Journal Home
Search for

Volume 24, Issue 1, Pages 51-70 (February 2010)


View previous. 8 of 14 View next.

Targeting subchondral bone for treating osteoarthritis: what is the evidence?

Steeve Kwan Tat, PhD (Post-doctoral student, University of Montreal), Daniel Lajeunesse, PhD (Professor of Medicine, Director of Biomedical Sciences, University of Montreal), Jean-Pierre Pelletier, MD (Professor of Medicine, University of Montreal; Head, Arthritis Centre, University of Montreal; Director, Osteoarthritis Research Institute), Johanne Martel-Pelletier, PhD (Professor of Medicine, University of Montreal; Director, Osteoarthritis Research Institute)Corresponding Author Informationemail address

Over the past few decades, significant progress has been made with respect to new concepts about the pathogenesis of osteoarthritis (OA). This article summarises some of the knowledge we have today on the involvement of the subchondral bone in OA. It provides substantial evidence that changes in the metabolism of the subchondral bone are an integral part of the OA disease process and that these alterations are not merely secondary manifestations, but are part of a more active component of the disease. Thus, a strong rationale exists for therapeutic approaches that target subchondral bone resorption and/or formation, and data evaluating the drugs targeting bone remodelling raise the hope that new treatment options for OA may become available.

Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, 1560 Sherbrooke Street East, Montreal, Quebec H2L 4M1, Canada

Corresponding Author InformationCorresponding author. Tel.: +1 514 890 8000x26658; fax: +1 514 412 7582.

PII: S1521-6942(09)00087-4

doi:10.1016/j.berh.2009.08.004


View previous. 8 of 14 View next.